Marc-Olivier Deguise

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4216332/publications.pdf

Version: 2024-02-01

24 papers 405 citations

1040018 9 h-index 940516 16 g-index

25 all docs

25 docs citations

25 times ranked

402 citing authors

#	Article	IF	CITATIONS
1	Survival motor neuron protein deficiency alters microglia reactivity. Glia, 2022, , .	4.9	7
2	Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy. Gene Therapy, 2022, 29, 544-554.	4.5	6
3	SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 354-377.e3.	4.5	16
4	Metabolic Dysfunction in Spinal Muscular Atrophy. International Journal of Molecular Sciences, 2021, 22, 5913.	4.1	18
5	Motor transmission defects with sex differences in a new mouse model of mild spinal muscular atrophy. EBioMedicine, 2020, 55, 102750.	6.1	17
6	Blood Flow to the Spleen is Altered in a Mouse Model of Spinal Muscular Atrophy. Journal of Neuromuscular Diseases, 2020, 7, 315-322.	2.6	8
7	Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2019, 6, 1519-1532.	3.7	72
8	Low fat diets increase survival of a mouse model of spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2019, 6, 2340-2346.	3.7	10
9	Into the unknown. , 2019, , 27-52.		1
10	P.068 Abnormal fatty acid metabolism is a feature of spinal muscular atrophy. Canadian Journal of Neurological Sciences, 2019, 46, S32.	0.5	0
11	Impaired kidney structure and function in spinal muscular atrophy. Neurology: Genetics, 2019, 5, e353.	1.9	28
12	SMA CLINICAL DATA, OUTCOME MEASURES AND REGISTRIES. Neuromuscular Disorders, 2018, 28, S57.	0.6	0
13	Interventions Targeting Glucocorticoid-Kr $ ilde{A}^{1}$ /appel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. EBioMedicine, 2018, 31, 226-242.	6.1	37
14	Oligodendrocyte development and CNS myelination are unaffected in a mouse model of severe spinal muscular atrophy. Human Molecular Genetics, 2017, 26, ddw385.	2.9	9
15	The role of the TWEAK/Fn14 pathway in muscle pathology in SMA. Neuromuscular Disorders, 2017, 27, S30.	0.6	O
16	The glucocorticoid-KLF15-BCAA pathway as a novel therapeutic target for spinal muscular atrophy. Neuromuscular Disorders, 2017, 27, S28-S29.	0.6	0
17	Abnormal fatty acid metabolism is a feature of spinal muscular atrophy. Neuromuscular Disorders, 2017, 27, S132-S133.	0.6	O
18	New insights into SMA pathogenesis: immune dysfunction and neuroinflammation. Annals of Clinical and Translational Neurology, 2017, 4, 522-530.	3.7	35

#	Article	lF	CITATIONS
19	Contributions of Different Cell Types to Spinal Muscular Atrophy Pathogenesis. , 2017, , 167-181.		3
20	Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. Human Molecular Genetics, 2017, 26, ddw434.	2.9	44
21	Differential induction of muscle atrophy pathways in two mouse models of spinal muscular atrophy. Scientific Reports, 2016, 6, 28846.	3. 3	24
22	MD/PhD Training in Canada: Results from a national trainee and program director review. Clinical and Investigative Medicine, 2016, 39, 132.	0.6	9
23	Acute Stroke Research: Being Part of a Game-Changer with Dr. Dar Dowlatshahi, Scientific Director of the Ottawa Stroke Program. University of Ottawa Journal of Medicine, 2015, 5, 8-11.	0.0	0
24	Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy. Human Molecular Genetics, 2014, 23, 4249-4259.	2.9	59